Do GLP-1 Drugs Affect Mental Health? A Systematic Review of Psychiatric Effects | Research

The takeaway

GLP-1 drugs show modest antidepressant effects and may help with addiction and eating disorders, but their link to suicidal thoughts remains unclear.

Modest antidepressant effect
Across multiple studies, GLP-1 receptor agonists showed consistent but modest improvements in depression symptoms

What the researchers found

This systematic review of GLP-1 receptor agonist psychiatric effects found a mixed but intriguing picture: modest antidepressant effects were observed across studies, and there were signs of potential benefit for eating disorders and substance use disorders — conditions driven by reward system dysregulation. However, the link between GLP-1 drugs and suicidal thoughts remained inconclusive, with studies showing inconsistent results. In people with schizophrenia, GLP-1 drugs improved metabolic health but did not consistently affect psychiatric symptoms.

Why it matters

With tens of millions of people now taking GLP-1 drugs like semaglutide and tirzepatide, understanding their effects on mental health is critical. Reports of reduced alcohol cravings, changed relationships with food, and concerns about suicidal ideation have made headlines. This review is the first systematic attempt to sort signal from noise across the full spectrum of psychiatric effects — and the answer is that some effects look real (antidepressant, anti-craving) while others (suicidality) remain unresolved.

How the study worked

The researchers systematically searched PubMed/MEDLINE, Cochrane Central Register, Embase, and Web of Science for all studies examining associations between GLP-1 receptor agonists and psychiatric outcomes including depression, suicidality, eating disorders, substance use disorders, and schizophrenia. Studies were evaluated for quality and findings were synthesized narratively across each psychiatric domain.

Who was studied

Systematic review covering studies of adults taking GLP-1 receptor agonists for diabetes, obesity, or both

What this study cannot tell us

The included studies varied widely in dosing, clinical indication (diabetes vs. obesity), and whether patients had pre-existing psychiatric conditions. People with psychiatric comorbidities were consistently underrepresented in the original trials. Sample diversity was limited across studies. The heterogeneity made it difficult to draw firm conclusions, particularly about suicidality risk.

How to read the evidence

This is a systematic review — a rigorous study type that follows a predefined search protocol across multiple databases. However, the underlying studies varied significantly in design, and the review was narrative rather than a quantitative meta-analysis, limiting the strength of its conclusions.

When this study was published

Published in early 2026, this is one of the most current systematic reviews on GLP-1 drugs and psychiatric effects. It captures the latest evidence on a rapidly evolving topic that has been the subject of FDA investigation and intense public interest.

The bigger picture

GLP-1 receptors are found throughout the brain, not just in the gut and pancreas. This means GLP-1 drugs almost certainly affect brain function in ways we're still discovering. The observation that people on these drugs sometimes lose interest in alcohol, gambling, or compulsive eating suggests they may modulate the brain's reward system. If confirmed, this could open entirely new therapeutic uses for GLP-1 drugs — but the suicidality question needs resolution first, especially given the scale of prescribing.

Questions still open

Do GLP-1 drugs directly affect brain reward circuits, or are the psychiatric benefits secondary to weight loss and metabolic improvement?
Should patients with pre-existing depression or suicidal ideation be monitored differently when starting GLP-1 medications?
Could GLP-1 drugs eventually be prescribed specifically for substance use disorders or binge eating?

Common questions

Do GLP-1 drugs cause suicidal thoughts?

The evidence is inconclusive. Some reports raised concerns, prompting an FDA investigation, but this systematic review found inconsistent results across studies — some showed no association, while others couldn't rule it out. People with psychiatric comorbidities were underrepresented in most trials, which makes it harder to answer this question definitively.

Why would a diabetes/weight loss drug affect mental health at all?

GLP-1 receptors aren't just in your gut — they're also found in brain areas that regulate mood, reward, and motivation. When GLP-1 drugs activate these brain receptors, they may influence how you experience pleasure, cravings, and emotional states. This is why some people report changes in their relationship with food, alcohol, and other substances.

Read the original research

Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence.

Diabetes, obesity & metabolism, 28(1), 50-59

View on PubMed ↗Publisher’s paper ↗

Citation

Sa, Brianna; Maristany, Anthony; Subramaniam, Ashwin; Guillen, Ryan; Buonocore, Brooke; Smith, Audrey; Oldak, Sean E; Padilla, Vanessa. (2026). Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence.. Diabetes, obesity & metabolism, 28(1), 50-59. https://doi.org/10.1111/dom.70198